Abiopharma

🔍 DeByle Thomas D. (Executive)

Company: AstroNova, Inc. (ALOT)

Report Date: 2026-08-26

Detailed Transactions and Holdings:

• Sold 6,170 shares of Common Stock at $29.0 per share (Direct)
  Date: 2026-08-26 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 6,886 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-26 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2
• Sold 6,790 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-26 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F3
• Sold 87,183 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-26 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4
• Sold 15,483 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-26 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5, F5

Footnotes:

• F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated as of June 16, 2026, by and among AstroNova, Inc. (the "Company"), Orion Merger Parent, Inc. ("Parent"), and Orion MergerCo X, Inc., a wholly owned subsidiary of Parent (as it may be amended from time to time, the "Merger Agreement").
• F2: Restricted Stock Units originally granted on April 14, 2025, which became fully vested and were cancelled on the Transaction Date as provided for in the Merger Agreement in exchange for an aggregate cash payment of $199,694, representing an amount equal to the number of shares of Common Stock underlying such Restricted Stock Units multiplied by the Merger Consideration.
• F3: Restricted Stock Units originally granted on April 15, 2025, which became fully vested and were cancelled on the Transaction Date as provided for in the Merger Agreement in exchange for an aggregate cash payment of $196,910, representing an amount equal to the number of shares of Common Stock underlying such Restricted Stock Units multiplied by the Merger Consideration.
• F4: Restricted Stock Units originally granted on August 15, 2025, which became fully vested and were cancelled on the Transaction Date as provided for in the Merger Agreement in exchange for an aggregate cash payment of $2,528,307, representing an amount equal to the number of shares of Common Stock underlying such Restricted Stock Units multiplied by the Merger Consideration.
• F5: Restricted Stock Units originally granted on February 26, 2026, which became fully vested and were cancelled on the Transaction Date as provided for in the Merger Agreement in exchange for an aggregate cash payment of $449,007, representing an amount equal to the number of shares of Common Stock underlying such Restricted Stock Units multiplied by the Merger Consideration.